| Document |
Document Title |
|
WO/2005/055941A2 |
Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.
|
|
WO/2005/055715A2 |
Certain noel N-(heteroarylalkyl)alkanediamine derivatives have provided unexpected insecticidal and acaricidal activity. These compounds are represented by formula I: wherein Ar, a, r, R, Ra, Rb, Rc, Rd, b, c, Re, Rf, Rg, Rh, R5, d, e, U...
|
|
WO/2005/056538A1 |
This invention provides compounds of the formula: wherein A', X and Y are defined in the specification. These compounds are useful as antibacterial agents.
|
|
WO/2005/056537A1 |
The present invention provides the glucagon-like peptide-1 receptor agonists. It is indicated that the agonists have good binding capability to glucagon-like peptide-1 receptor by pharmacological tests. The present invention also provide...
|
|
WO/2005/054194A1 |
A method for the synthesis of a compound of formula (I) as a mixture of enantiomers, formula (I) (wherein R1 is H or an acid protective group and H+A- indicates an optional acid with which the compound of formula (I) may form an ammonium...
|
|
WO/2005/053631A1 |
The invention provides a process for producing microcapsules with UV filter activity, wherein at least one type of crosslinkable chromophore with UV-A and/or UV-B and/or UV-C filter activity and optionally at least one type of crosslinka...
|
|
WO/2005/051932A1 |
Arylheterocycle derivatives which are represented by the formula (1): (1) wherein R1 represents C1-6 alkyl, etc.; R2 represents halogeno, etc.; m is an integer of 0 to 4; and T represents a group represented by the formula (2), (3), or (...
|
|
WO/2005/051933A1 |
Provided herein are process for the synthesis of the 4-(4-benzyloxy-carbonylamino-2-fluorophenyl)-piperazine-1-ca
rboxylic acid tert-butyl ester, which is a key intermediate in the synthesis of oxazolidinone compounds having antibacteria...
|
|
WO/2005/051110A1 |
Girdles (short, long) capable of improving the posture of a wearer by acting on muscle around a pelvis, capable of being easily handled, and capable of being worn without uncomfortable feeling, wherein fastening parts in which the magnit...
|
|
WO/2005/049018A1 |
The present invention relates to modulators of ATP-Binding Cassette ('ABC') transporters or fragments thereof, including Cystic Fibrosis Transmembrane Regulator ('CFTR'), compositions thereof, and methods therewith. The present invention...
|
|
WO/2005/049592A1 |
The invention provides a process for preparing intermediate of ezetimibe, which shows hypocholesterolemic activity. Thus 3-[5-(4-fluorophenyl)-1,5-dioxopentyl]-4-phenyl-2-oxazolidin
one is reduced with (-)-DIP chloride to obtain 3-[(5S)-...
|
|
WO/2005/049593A2 |
Disclosed are N-acylsulfonamide compounds which inhibit the activity of anti-apoptotic protein family members, compositions containing the compounds and uses of the compounds for preparing medicaments for treating diseases during which a...
|
|
WO/2005/049594A1 |
Disclosed are N-acylsulfonamide compounds which inhibit the activity of anti-apoptotic protein family members, compositions containing the compounds and uses of the compounds for preparing medicaments for treating diseases during which o...
|
|
WO/2005/049589A2 |
Disclosed are novel compounds of formula (I), having hypolipidaemic and hypocholesterolemic properties, their tautomeric forms, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acce...
|
|
WO/2005/047271A1 |
Disclosed is a process for preparing a 6-chloro-2,5-dicarbonamido phenol compounds comprising a step employing a 2-alkyl-6-aminobenzoxazole to form a 2-alkyl-6-amino-7-chlorobenzoxazole in which the 2-alkyl group is unbranched at the &ag...
|
|
WO2005016898B1 |
The invention relates to a stable polymorphic form of the compound 7-[4-([1,1'-biphenyl] -3-ylmethyl)-l -piperazinyl]2(3H)-benzoxazolone monomethanesulfonate (INNM bifeprunox mesylate), a method for the preparation of said polymorphic ...
|
|
WO2005012220A9 |
The present invention relates to novel compounds with a variety of therapeutic uses, more particularly novel substituted cyclic alkylidene compounds that are particularly useful for selective estrogen receptor modulation. Formula (I) inc...
|
|
WO/2005/044256A1 |
The instant invention provides novel cholesterol absorption inhibitors of Formula I and the pharmaceutically acceptable salts and esters thereof. The compounds are useful for lowering plasma cholesterol levels, particularly LDL cholester...
|
|
WO/2005/044804A1 |
The invention relates to a method for the production of fluoromethyl-substituted heterocycles of formula (I), where R1, R2 , R3 and A have the meanings given in the description, by fluorination of the corresponding chloromethyl-substitut...
|
|
WO/2005/040121A2 |
The present invention relates to compounds of formula (I), that are novel VR1 antagonists useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence, or bladder overactivity.
|
|
WO/2005/040129A2 |
The present invention relates to compounds of Formula (I), wherein R2, R3, R4, R9, Ar, UC, X, Y, Q, n and p are as defined in the specification. The compounds are useful as CCR-3 receptor antagonists, and therefore, may be used for treat...
|
|
WO/2005/040161A1 |
The present invention relates to hydroxamate compounds which are inhibitors of histone deacetylase. More particularly, the present invention relates to biaryl containing compounds and methods for their preparation. These compounds may be...
|
|
WO/2005/040127A1 |
The present invention relates to novel compounds accelerating the activity of Peroxisome proliferator-activated receptor gamma (PPAR&gammad ) and alpha (PPAR&agr ), processes of preparing the same, and pharmaceutical compositions contain...
|
|
WO/2005/040355A2 |
The invention provides compounds and methods for inhibition of kinases, such as those of the TAO family, more specifically KIAA1361, TAO, and JIK kinases. The invention provides compounds for modulating protein kinase enzymatic activity ...
|
|
WO/2005/040138A1 |
This invention is related to compounds of general formula (I) wherein X is oxygen or sulphur or a NR7 group; R1 is C3-C8 alkyl, or C1-C8 alkyl substituted by phenoxy or phenyl, both phenoxy or phenyl being optionally substituted by one o...
|
|
WO/2005/040139A2 |
The present invention relates to novel compounds selected from 2-aminoaryloxazoles of formula I that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant tyrosine kinases implicated ...
|
|
WO/2005/040109A1 |
Compounds which function as melanocortin receptor ligands and having utility in the treatment of melanocortin receptor-based disorders. The compounds have the following structure (I): (R4)s (R 2)n N˜ X1-X2 (CR1aCRlb)q 1˜ N R1-lm 1 O R3...
|
|
WO/2005/039570A1 |
A TGF-β information transfer pathway inhibitor comprising a low-molecular compound capable of inhibiting TGF-β information transfer pathway. There is provided a TGF-β information transfer pathway inhibitor comprising as an active ingr...
|
|
WO/2005/037829A1 |
The invention relates to compounds of formula 1, the production and use thereof as a medicament for the treatment of diseases, particularly tumours and/or diseases caused, mediated or propagated by angiogenesis. The compounds of formula ...
|
|
WO/2005/035530A1 |
The present invention relates to a novel crystalline form of linezolid, to processes for its preparation and to a pharmaceutical composition containing it.
|
|
WO/2005/035510A1 |
The invention relates to novel derivatives of 4-phenylthiazoles and 4-phenylimidazoles and the use thereof as medicaments. The invention especially relates to the following compounds: butyl-2-[4-(4-aminophenyl)-1H-imidazol-2-yl]ethylcarb...
|
|
WO/2005/033087A1 |
Disclosed is a heterocycle-substituted phenylacetylene compound represented by the following formula (1): (1) , wherein n1 is an integer of 1-3; A represents a hydrogen atom, an alkyl group, a cycloalkyl group, an aryl group, an aralkyl ...
|
|
WO/2005/033106A1 |
The invention discloses a novel heterocyclic compounds that falls within f the ambit of general formula (I), its stereoisomers, pharmaceutically acceptable salts or solvates wherein X, n,k,z, R1, R2, R3, R4, R5 and R6 are as defined in t...
|
|
WO/2005/030700A2 |
Certain ß-amino acids that bind to the alpha-2-delta (a2S) subunit of a calcium channel are disclosed. These compounds and their pharmaceutically acceptable salts are useful in the treatment of a variety of psychiatric, pain and other d...
|
|
WO/2005/030736A1 |
A description follows of 1,3-diones having general formula (I): together with their use as herbicides for the control of weeds in agricultural crops.
|
|
WO/2005/030704A1 |
The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell pr...
|
|
WO/2005/030739A1 |
The present invention relates to methods for the preparation of benzoxazole sulfonamide compounds of formula (9) as well as novel intermediates of formula (6) for use in said method. More in particular the invention relates to methods fo...
|
|
WO/2005/028445A2 |
Compounds of formula (I): wherein A, B and D are each C, N, O or S; E is C or N; the dotted circle within the five-membered ring indicates that the ring may be unsaturated or partially saturated;. R 1 is halogen, hydroxy, C 1-6 álkyl, h...
|
|
WO/2005/028454A1 |
The application is directed to haloalkyl-substituted compounds of Formula (I), wherein R1, R1a, R2, R3, R4’ and E are as defined in the claims. The compounds are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, a...
|
|
WO/2005/028426A1 |
A compound of the present invention and pharmaceutically acceptable salts thereof are represented by the following general formula (1). (1) (In the formula (1), the definitions of R1, R2, R3, R4, R5, R6, Q, R8 and R9 are the same as thos...
|
|
WO/2005/028413A1 |
A process for producing an optically active cyclopropane compound represented by the formula (4): (4) (wherein R3, R4, R5, and R6 are the same or different and each represents hydrogen, halogeno, (un)substituted alkyl, etc.; R7 represent...
|
|
WO/2005/026114A1 |
This invention relates to a novel series of chemical compounds useful as Human immunodeficiency Virus (HIV) protease inhibitors and to the use of such compounds as antiviral agents. The invention further relates to pharmaceutical composi...
|
|
WO/2005/026137A2 |
The present invention relates to modulators of ATP-Binding Cassette ('ABC') transporters or fragments thereof, including CF Transmembrane Regulator ('CFTR'), compositions thereof, and methods therewith. The present invention also relates...
|
|
WO/2005/026134A1 |
Compounds of the formula (I) provide pharmacological agents which bind to Peroxisome Proliferator-Activated Receptors (PPARs). Accordingly, the compounds of the present invention are useful for the treatment of conditions mediated by the...
|
|
WO/2005/023765A1 |
The invention provides a method of preparing a compound of formula (2), wherein R1 and R6 are as defined herein, by a catalytic amidation process in the presence of added carbon dioxide. The inventive methods show surprising rate enhance...
|
|
WO/2005/023261A1 |
The invention relates to compounds of formula (I) wherein Ar is substituted aryl or unsubstituted or substituted 6-membered heteroaryl, containing one, two or three nitrogen atoms, and wherein the aryl and the heteroaryl groups may be su...
|
|
WO/2005/023801A1 |
The invention relates to intermediate products (ZP) for a novel and efficient synthesis of compounds, wherein the pharmacophores of quinolone and oxazolidinone are linked together by means of a chemically stable linker.
|
|
WO/2005/023777A1 |
Disclosed is a compound for selectively activating PPAR &agr which is represented by the following general formula (1): (1) (wherein R1 and R2 may be the same or different and represent hydrogen atoms or the like; R3a, R3b, R4a and R4b m...
|
|
WO2004074270B1 |
The invention relates to compounds of the formula (I) and to pharmaceutically acceptable salts, solvates, prodrugs and metabolites thereof, wherein W, Z, R<1> and R<2>, are as defined herein. The invention also relates to methods of trea...
|
|
WO/2005/021503A1 |
Compounds of formula (I): wherein R1, R2, n and m are as defined in the specification, processes for their production, their uses and pharmaceutical compositions containing them.
|
